GYN: Endometrial/Uterine Cancer Clinical Trials

Showing 1-10 of 10 items
1.
  • Image-Guided Gynecologic Brachytherapy
  • Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.
  • Diagnoses: GYN: Cervical Cancer, GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
2.
  • PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
  • MK-2206 is a drug that may stop cancer cells from growing. MK-2206 blocks a signal inside the cell that can cause abnormal cell growth. This drug has been used in other research studies and information from those studies suggests that this agent may help to keep cancer from growing in this research study. The investigators are looking to see how effective MK-2206 is in treating recurrent and metastatic endometrial cancer. Additionally, the investigators are looking to see if participants whose tumors contain a particular genetic make-up will have a better response to MK-2206. Participants' tumors will be tested for a mutation in a gene called PIK3CA, which makes a protein that helps cell to use energy and grow.
  • Diagnoses: GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
3.
4.
  • VB-111+Paclitaxel for Recurrent Mullerian Cancer
  • This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved VB-111, or the combination of VB-111 with paclitaxel for use in patients, including people with your type of cancer. VB-111 is designed to kill cancer cells in the body by "cutting off" the blood flow to cancer cells and/or tumors. The process of "cutting off" the blood flow to cancer cells and/or tumors is known as anti-angiogenesis and has been shown to help prevent tumor growth. VB-111 is both a vascular disrupting (blocking blood vessels) and anti-angiogenic (preventing new blood vessel growth) agent. It is different to normal chemotherapy as it is made from an adenovirus (Cold virus) carrying a human gene that kills cell lining blood vessels (Endothelial cells). This virus is a 'non-replicating' virus, meaning it cannot grow in the body. Paclitaxel is a chemotherapy drug which is FDA approved for use in your type of cancer. In this research study, we are looking for the highest dose of VB-111 that can be given safely in combination with paclitaxel to patients with platinum-resistant ovarian cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer, GYN: Endometrial/Uterine Cancer
  • Status: Recruiting
5.
6.
  • PET-CT vs. Integrated MR-PET Scanning of GYN Cancers
  • This research study is an imaging pilot study. Imaging pilot studies explore the potential benefit of one imaging approach compared to another clinically accepted approach. Such studies serve to understand how feasible an approach may be and whether it is worth pursuing in formal and larger clinical trials. Researchers of this study believe that simultaneous Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) imaging will offer additional imaging information to improve cancer detection. MRI and PET are two tests that allow us to take pictures of the body and "look inside" the body without surgery. The MRI scanner uses a powerful magnet to make a picture of the body. The PET scanner makes pictures by using special dyes that "light up" inside the body. PET scans use radiation, similar to the radiation in a standard x-ray. We routinely use both tests to diagnose various types of cancer. As of now, the combination of PET and computed tomography (CT) has been considered a standard of care imaging approach for various cancers. Until recently, MRI and PET tests were done separately. Now there is a new type of test called MR-PET that combines both MRI and PET test results. This scanner uses both MRI and PET tests at the same time. We would like to find out if the MR-PET scanner can produce better and clearer images (pictures) of tumors and information about them inside of the body. This new MR-PET scanner is approved by the US FDA. However, some of the computer programs that tell the machine how to acquire and combine the test results are new and experimental. Experimental means that some of the computer programs are not approved by the FDA. This means that they can only be used in research studies. The MR-PET scanner has been previously used in a few human participants.
  • Diagnoses: GYN: Endometrial/Uterine Cancer, GYN: Cervical Cancer, GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
7.
8.
9.
10.
Showing 1-10 of 10 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms